EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunological Profiles in Parry–Romberg Syndrome: A Case–Control Study

Irma Saulle iD, Antonio Gidaro iD, Mattia Donadoni, Claudia Vanetti iD, Alessandra Mutti, Maria Eva Romano, Mario Clerici iD, Chiara Cogliati, Mara Biasin iD

Journal of Clinical Medicine · 21.02.2024 · 13 (5) · 1219

DOI: 10.3390/jcm13051219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.02.2024. Verfasst von Irma Saulle und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Clinical Sciences, University of Milan, 20157 Milan, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PNRR, Fondazione Alessandro and Vincenzo Negroni Prati Morosini, Fondazione Romeo and Enrica Invernizzi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parry–Romberg syndrome (PRS) is a rare craniofacial disorder. The aim of this study is to provide information on the immunological profile of this pathology. Since PRS can be included in a wider spectrum of sclerodermic diseases, we propose a case–control study comparing a patient affected by PRS with one with a diagnosis of scleroderma, herein used as control (CTR).

Methods

B lymphocyte, T lymphocyte, and monocyte phenotypes and functions were assessed by flow cytometry in influenza (Flu)- or anti cluster differentiation (CD)3/CD28-stimulated peripheral blood mononuclear cells (PBMCs). Cytokine concentration was evaluated as well in PBMC supernatants, plasma, and saliva by Luminex assay.

Results

T and B lymphocytes were similarly activated in unstimulated PRS and CTR cells but differed following antigen stimulation. T helper (Th)17 lymphocytes were expanded in PRS compared to CTR; this increase correlated with higher interleukin (IL)-17 concentration.

Conclusions

Our case–control study is the first to compare the immunological profiles of PRS and scleroderma patients. The higher percentage of Th17 cells in PRS suggests the use of anti-IL17 receptor monoclonal antibody in this rare disease; however, further studies with larger numbers of patients are needed to confirm our findings.

Schlagwörter

Stichwörter der Autor:innen

Parry–RombergTh17immunological profile

Autor:innen und Institutionen

  • Department of Biomedical and Clinical Sciences, University of Milan, 20157 Milan, Italy.
  • Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
  • Department of Rheumatology, Luigi Sacco Hospital, 20157 Milan, Italy.
  • Don C. Gnocchi Foundation, IRCCS, 20122 Milan, Italy.

ORCID-Profile: Irma Saulle, Antonio Gidaro, Claudia Vanetti, Mario Clerici, Mara Biasin

Förderung

  • PNRR
  • Fondazione Alessandro and Vincenzo Negroni Prati Morosini
  • Fondazione Romeo and Enrica Invernizzi
  • PNRR-Spoke 13-CUP-G43C2200260007-INF-ACT

Zitieren

APA

Saulle, I., Gidaro, A., Donadoni, M., Vanetti, C., Mutti, A., Romano, M. E., Clerici, M., Cogliati, C., & Biasin, M. (2024). Immunological Profiles in Parry–Romberg Syndrome: A Case–Control Study. Journal of Clinical Medicine, 13(5), 1219. https://doi.org/10.3390/jcm13051219

Vancouver

Saulle I, Gidaro A, Donadoni M, Vanetti C, Mutti A, Romano ME, et al. Immunological Profiles in Parry–Romberg Syndrome: A Case–Control Study. Journal of Clinical Medicine. 2024;13(5):1219. doi:10.3390/jcm13051219

BibTeX
@article{Saulle2024,
  author = {Saulle, Irma and Gidaro, Antonio and Donadoni, Mattia and Vanetti, Claudia and Mutti, Alessandra and Romano, Maria Eva and Clerici, Mario and Cogliati, Chiara and Biasin, Mara},
  title = {Immunological Profiles in Parry–Romberg Syndrome: A Case–Control Study},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {5},
  pages = {1219},
  doi = {10.3390/jcm13051219}
}
Kostenlos starten →